Validation and comparison of the das28 definition based on CRP with the das28 based on ESR using data from patients with rheumatoid arthritis treated with ABATACEPT

被引：0

作者：

Wells, G. ^{[1
]}

Becker, J. ^{[2
]}

Teng, J. ^{[2
]}

van Riel, P. ^{[3
]}

机构：

[1] Univ Ottawa, Ottawa, ON, Canada

[2] Bristol Myers Squibb Co, Princeton, NJ USA

[3] Univ Nijmegen Hosp, NL-6500 HB Nijmegen, Netherlands

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：440 / 440

页数：1

共 3 条

[1]

Fransen J, 2005, CLIN EXP RHEUMATOL, V23, pS93

[2] Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition [J].

Genovese, MC ;

Becker, J ;

Schiff, M ;

Luggen, M ;

Sherrer, Y ;

Kremer, J ;

Birbara, C ;

Box, J ;

Natarajan, K ;

Nuamah, I ;

Li, T ;

Aranda, R ;

Hagerty, DT ;

Dougados, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (11) :1114-1123

[3] Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept - Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial [J].

Kremer, JM ;

Dougados, M ;

Emery, P ;

Durez, P ;

Sibilia, J ;

Shergy, W ;

Steinfeld, S ;

Tindall, E ;

Becker, JC ;

Li, T ;

Nuamah, IF ;

Aranda, R ;

Moreland, LW .

ARTHRITIS AND RHEUMATISM, 2005, 52 (08) :2263-2271

← 1 →